欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
支气管哮喘是一种以Th2优势免疫为特征的气道过敏性疾病，其中嗜酸粒细胞性气道炎症、气道高反应性和气道重塑为哮喘三个主要的临床特征。Dupilumab 是抗 IL-4受体α亚基（IL-4Rα）的单抗，能抑制IL-4Rα与IL-4和IL-13结合并阻断其介导的下游信号转导，从而抑制哮喘气道炎症、气道高反应性和气道重塑的发生发展。本文将就Dupilumab治疗嗜酸粒细胞增高的中重度持续性哮喘的研究进展作一综述。
英文摘要：
Bronchial asthma is a Th2 immunity-dominated common airway allergic disease, characterized by eosinophilic airway inflammation, airway hyperresponsiveness and airway remodeling. Dupilumab,a novel monoclonal antibody targeting the α-subunit of IL-4 receptor （IL-4Rα）, is capable of binding with IL-4Rα to block both IL-4 and IL-13-mediated signaling pathways, leading to inhibit the airway inflammation, hyperresponsiveness and remodeling. This paper focused on the progress of Dupilumab in persistent moderate-to-severe asthma with elevated eosinophil levels.
同期刊论文项目
同项目期刊论文
Prognostic value of chronic obstructive pulmonary disease assessment test, serum copeptin, procalcit
Quantitative CT measures of pectoralis muscle area and disease severity in COPD: a cross-sectional s
期刊信息
位置：